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irculating Endothelial Cells in Cardiovascular Disease
hristopher J. Boos, MRCP, Gregory Y. H. Lip, MD, Andrew D. Blann, PHD
irmingham, United Kingdom
Quantification of circulating endothelial cells (CECs) in peripheral blood is developing as a
novel and reproducible method of assessing endothelial damage/dysfunction. The CECs are
thought to be mature cells that have detached from the intimal monolayer in response to
endothelial injury and are a different cell population to endothelial progenitor cells (EPCs).
The EPCs are nonleukocytes derived from the bone marrow that are believed to have
proliferative potential and may be important in vascular regeneration. Currently accepted
methods of CEC quantification include the use of immunomagnetic bead separation (with
cell counting under fluorescence microscopy) and flow cytometry. Several recent studies have
shown increased numbers of CECs in cardiovascular disease and its risk factors, such as
unstable angina, acute myocardial infarction, stroke, diabetes mellitus, and critical limb
ischemia, but no change in stable intermittent claudication, essential hypertension, or atrial
fibrillation. Furthermore, CEC quantification at 48 h after acute myocardial infarction has
been shown to be an accurate predictor of major adverse coronary events and death at both
1 month and 1 year. This article presents an overview of the pathophysiology of CECs in the
setting of cardiovascular disease and a brief comparison with EPCs. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.0782006;48:1538–47) © 2006 by the American College of Cardiology Foundation
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dardiovascular disease (CVD) is the leading cause of death
nd disability in the developed world, and is projected to
oon overtake infectious disease as the preeminent cause of
eath worldwide. Accounting for 49% of all deaths in
urope and 30% of all deaths before the age of 65 years, it
ontributes substantially to the escalating cost of health care
1–3). The reasons for this generally reflect an increasing
revalence of several known CVD risk factors: obesity and
nsulin resistance, diabetes, smoking, hypertension, poor
iet, and an increasing ageing population (2,4). The spec-
rum of CVD is wide and includes coronary artery disease
CAD), peripheral vascular disease (PVD), congestive heart
ailure, and atrial fibrillation (AF), stroke, in addition to the
ajor risk factors of hypertension, hypercholesterolemia,
moking, and diabetes mellitus. A commonality between
hese conditions is the loss of appropriate endothelial
hysiology (damage/injury, leading to dysfunction) that is
aramount to the maintenance of vascular hemostasis and
lood pressure control (5).
However, it is now recognized that up to half of patients
resenting with a clinical manifestation of CVD do not
ossess any of the traditional risk factors (4). Hence, there
s growing interest in the identification of other risk factors
r markers (such as for assessing vascular injury) that may
acilitate improved measures for the primary and secondary
revention of CVD (5). Methods for assessing endothelial
unction include the quantification of changes in coronary
nd brachial artery blood flow (the latter generally referred
From the Haemostasis, Thrombosis, and Vascular Biology Unit, University
epartment of Medicine, City Hospital, Birmingham, United Kingdom. Cardiovas-
ular Genomic Medicine series edited by Geoffrey S. Ginsburg, MD, PhD.s
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006, accepted February 14, 2006.o as flow-mediated dilatation [FMD]) and abnormal re-
ease of plasma markers such as von Willebrand factor
vWf) (6–8). More recently, the measurement of immuno-
ogically defined circulating endothelial cells (CECs) in the
eripheral blood is gaining ground as an important and
ovel technique for assessment of endothelial injury. The
ECs are part of a family of blood-borne endothelioid cells
hat include endothelial progenitor cells (EPCs).
In this article we present a comprehensive overview of the
athophysiology of CECs and the value of CEC quantifi-
ation as an important marker for CVD, and briefly com-
are them with EPCs. To do this we performed an on-line
earch of the publication databases Cochrane Reviews,
ubMed, Medline, and Embase, using the key words
irculating endothelial cells and endothelial progenitor cells.
RIGINS OF CECs
ndothelial cells line the vascular tree and adhere to a
asement membrane. In health, these cells would be ex-
ected to remain in this location, with perhaps a very low
evel of cell loss into the blood, with consequent clearance by
he reticuloendothelial system. It would seem logical that
athological processes that cause damage to the endothe-
ium might also cause endothelial cell detachment, resulting
n increased numbers of CECs within the bloodstream (9).
he mechanism of CEC detachment is complex and
nvolves many factors, such as mechanical injury, the classic
isk factors for atherosclerosis, alteration of endothelial/
ubendothelium cellular adhesion molecules, defective bind-
ng to anchoring matrix proteins, and cellular apoptosis with
ecreased survival of cytoskeletal proteins (9 –11).
Current consensus supports the view that CECs repre-ent a different population of cells from EPCs. The latter
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October 17, 2006:1538–47 Circulating Endothelial Cellseem to be a heterologous population of largely bone
arrow–derived large nonleukocyte cells with properties
imilar to those of embryonal angioblasts, at different stages
f maturation, from early (vascular endothelial growth
actor receptor [VEGFR]/CD133) to a more mature
VEGFR/CD34) phenotype. The EPCs have many prop-
rties that distinguish them from CECs (i.e., viability,
orming colonies in vitro [12,13], and having the capacity to
ifferentiate into mature endothelial cells [14 –16]). Hence,
PCs represent a subset of cells at varying stages of
evelopment present in the peripheral bloodstream. In
ontrast, it is uncertain whether CECs are all truly viable
ecause they are less likely to form colonies (if at all), some
ppearing in the circulation as irregular carcasses, as clumps
f cells, or as filamentous cell remnants (9).
Broadly speaking, EPCs and CECs can be separated by
dentification of their surface markers: EPCs bear immatu-
ity surface markers, such as CD34 and CD133, whereas
ECs are positive for CD146 and negative for CD34 and
D133 (15–18). The CD146 molecule has clearly evolved
s the most popular marker for the identification of CECs.
his adhesion molecule is concentrated at the endothelial
unction, where it plays a key role in the control of cell–cell
ohesion, permeability, and signalization (19,20).
SOLATION OF CECs
lthough the precise quantification of CECs is difficult
partly because of the low numbers present in the circulation
nd because of their differing morphologic appearances),
heir detection has been improved by cell enrichment
echniques and cell labeling using relatively endothelial-
pecific markers. The CECs are counted in whole blood
sing either immunomagnetic separation or flow cytometry.
he former method [full details of which are available
lsewhere (9,17,21)] involves the use of 4.5-m ferrous
eads bound to an anti-CD146 monoclonal antibody.
riefly, these coated beads are mixed with venous blood in
head-over-head mixer for 30 min at 4°C. The anti-
D146–coated beads and blood/buffer mixture are placed
n front of a magnet. The anti-CD146–coated beads
typically 5  107/ml of blood) bind to the CD146 epitope
n the CECs and the magnet is then used to separate the
Abbreviations and Acronyms
AF  atrial fibrillation
CAD  coronary artery disease
CEC  circulating endothelial cell
CVD  cardiovascular disease
EPC  endothelial progenitor cell
FMD  flow-mediated dilatation
MI  myocardial infarction
PVD  peripheral vascular disease
VEGFR  vascular endothelial growth factor receptor
vWf  von Willebrand factoread-coated CECs from the other blood constituents. The cnbound cells are washed away with buffer, and bound cells
re retained on the magnet. After additional wash cycles,
he cells are resuspended in buffer and labeled (e.g., with
cridine orange) before manual counting in a glass counting
hamber under a fluorescent microscope. The use of an
c-blocking agent (to prevent nonspecific leukocyte bind-
ng) and relatively endothelial-specific Ulex europaeus lectin
 has improved the specificity of this technique (Fig. 1). A
EC is defined as an event of appropriate size that binds
forms a rosette with) 4 or more beads (21). The endothelial
and nonleukocyte) origin of CD146-defined CECs has
een amply shown by co-marking with, for example, vWf,
ndothelial nitric oxide synthase, and E-selectin; however, a
otable caveat (especially in cancer) is that CD146 may also
e found on trophoblasts, mesenchymal stem cells, peri-
dontal tissue, and malignant (prostatic, melanoma) tissues
9).
HE RELATIONSHIP BETWEEN CECs,
VD, AND ENDOTHELIAL DYSFUNCTION
urrent well-accepted methods used to quantify the severity
f endothelial damage/injury include vascular marker quan-
ification (e.g., vWf, soluble E-selectin, soluble thrombo-
odulin), reduced FMD, and impaired skin blood flow
esponse using laser Doppler flowmetry. There is a clearly
hown association between almost all types of CVD (CAD
22,23], PVD [24], hypertension [25,26], stroke [27], heart
ailure [28,29], AF [30 –32], and diabetes [33,34]) and the
ndothelial dysfunction that occurs after damage/injury. As
ndicated, the endothelial origin of CECs has been con-
rmed by the positive labeling for vWf, endothelial nitric
xide synthase, and E-selectin, but also for receptors for
EGF, the receptor of acetylated low-density lipoprotein
igure 1. A circulating endothelial cell (stained bright green with Ulex
uropaeus lectin) forming a rosette with at least 10 immunomagnetic beads.
hotomicrograph in epifluorescence (Zeiss), wet preparation, magnifica-
ion 40. For scale, the large number of residual immunomagnetic beads
ach have a diameter of 4.5 m.holesterol, thrombomodulin, and Ulex europaeus lectin
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Circulating Endothelial Cells October 17, 2006:1538–47and by the identification of Weibel-Palade bodies
17,18,21,35).
There is increasing evidence to support the relationship
etween CECs and endothelial dysfunction. For example,
n inverse correlation between CECs and FMD (a surrogate
hysiological marker of a disturbed endothelium) has been
hown (36,37). In addition, a strong correlation between
ECs and several plasma markers of endothelial injury
vWf, tissue plasminogen activator, soluble E-selectin) have
lso been shown (36–40). Figure 2 shows such a correlation
etween CECs and vWf in heart failure (39).
ECs AND DISEASE
he CECs are rarely found in normal healthy individuals, in
he order of 3 cells/ml. Elevated numbers of CECs have
een identified in a wide array of disease processes such as
hronic venous insufficiency (41), aortitis (42), pulmonary
ypertension (43), Behçet’s disease (44), septic shock (45),
reast cancer (46), acute sickle cell crises (47), and throm-
otic thrombocytopenia (48). Elevated CECs have also
een shown to correlate with disease severity in a variety of
iseases, including Mediterranean spotted fever (49), in-
ammatory vasculitis (18,50), Kawasaki disease (51), sys-
emic lupus erythematosus (52), and in systemic sclerosis
53).
The CECs have been identified as a useful marker of
ndothelial damage and potential vascular rejection in kid-
ey transplantation patients (54,55). Popa et al. (54) were
ble to show that the presence of donor CECs in recipient
lood related to post-transplantation injury. More recently,
oywodt et al. (56) showed that in allogenic hematopoietic
tem cell transplantation, those patients who received
educed-intensity conditioning had significantly lower CEC
umbers.
The endothelium plays an important role in the spread
nd propagation of cancer cells. It is actively involved in
ngiogenesis (new vessel formation) and in metastasis (57).
ncreased CECs have been identified in both breast cancer
nd lymphoma, and their numbers have been shown to
igure 2. Relationship of von Willebrand factor (vWf) and circulating
ndothelial cells (CECs) in heart failure. Spearman correlation, r  0.463;
 0.0001. Reprinted, with permission, from Chong et al. (37).ignificantly correlate with plasma vascular cell adhesion folecule-1 and VEGF levels, although these molecules are
ot endothelial-specific (46,58,59).
In various diseases, the longitudinal quantification of
ECs has shown that their levels vary according to the
linical condition/severity. Levels among patients who are
cutely ill are higher than in those patients who are in
linical remission or in a recovery phase of the disease. From
pharmacologic point of view, several studies have also
hown that CECs may be useful in monitoring therapeutic
fficacy. For example, Woywodt et al. (50) showed a
ecrease in CECs during 6 months of successful treatment
f anti-neutrophil cytoplasmic antibody–associated small-
essel vasculitis, whereas George et al. (60) showed a
ecrease in CECs with treatment of Rickettsial conorri
nfection in familial Mediterranean fever. In another study
nvolving the treatment of disseminated human cytomega-
ovirus infection, there was a dramatic decrease in the CEC
ount from blood within just a few days of treatment by
anciclovir and foscarnet (61). In addition, CEC numbers
re reported to be higher in those patients with progressive
isease compared with those who have stable disease and
ith healthy controls (62).
The precise anatomic origin of CECs, i.e., arterial or
enous, is unclear. However, several groups have used
D36 to show that in some circumstances, CECs may arise
rom the microvascular (47) or the macrovascular portion of
he vascular tree (63).
ECs IN CVD
AD. There have been several studies quantifying CECs
n myocardial infarction (MI) (17,39,63– 66) (Table 1).
espite small numbers, results are consistent: acute MI and
nstable angina are both associated with significantly in-
reased CEC counts compared with healthy controls, and
EC counts are either normal or only minimally elevated in
atients with stable angina. The CEC counts in patients
ith acute coronary syndromes correlate with endothelial
ysfunction (by measurement of vWf levels) and with the
rothrombotic state (measurement of tissue factor levels)
39). In the study by Wang et al. (66), the investigators
howed that CEC counts correlated with levels of inflam-
atory marker C-reactive protein, even after adjustment for
onfounding factors.
Quilici et al. (64) showed that the combined use of CEC
uantification with cardiac troponin measurement markedly
mproved diagnostic accuracy in patients presenting with
on–ST-segment elevation MI. In addition, they were able
o give some insight into the temporal pattern of CEC
ecrease. They showed that the highest CEC counts were
btained at the time of infarct presentation, with decreasing
evels over the ensuing 8 h, with a steady decrease thereafter.
owever, this is in contrast to the much smaller study (only
patients were studied for temporal data) by Mutin et al.
63), in which maximal CEC levels in serial samples were
ound at 18 to 24 h after MI.
Table 1. Studies Summarizing the Quantification of CECs in Coronary Artery Disease
Author Year
Method
of CEC
Isolation Patient Type
Number of
Patients
CEC Counts
(Cells/ml) Adjusted Variables Main Findings
George et al. (17) 1992 IB Post-angioplasty
Healthy controls
8–15
3
Nil There is a significant increase in CEC
from baseline in both venous and
arterial blood postangioplasty. There
is no significant difference in CEC
counts in arterial versus venous blood
samples.
Mutin et al. (63) 1999 IB Acute MI
Unstable angina
Stable CAD
Healthy controls
26
33
13
14
7.5 (1.5–43.5)
4.5 (0.8–133)
0
0
Nil CEC counts are increased in both acute
MI and unstable angina compared
with healthy controls and patients
with stable CAD (p  0.01).
Makin et al. (39) 2004 IB Acute MI
Healthy controls
20
20
4.9 (3.6–8.4)
1.0 (0.5–1.7)
Nil CEC counts are significantly higher in
patients with acute MI as compared
with healthy controls.
Quilici et al. (64) 2004 IB Non–ST-segment
elevation ACS
Control
60
40
8.5 (15–25.5)
3
Chest pain frequency and
interval between chest
pain and admission
Higher CEC counts with non–ST-
segment elevation ACS compared
with controls. The interval between
chest pain and elevation was shorter
for CEC than troponin I.
Lee et al. (65) 2005 IB Acute MI
Stable CAD
Healthy controls
156
36
40
10.6 (5.8–14.5)
3.1 (2.3–4.0)
2.75 (1.6–3.9)
Nil CEC counts elevated in acute MI
compared with stable CAD and
healthy controls. CEC counts were
predictive of 30-day and 1-year
MACE and death. CEC counts
correlated with IL-6 and vWf levels.
Wang et al. (66) 2005 IB Acute MI
Healthy controls
37
42
52 (28–81.5)
10.5 (6–16.5)
Age, gender, serum
cholesterol,
hypertension, obesity,
history of CVD, or
smoking
CEC counts were significantly higher in
patients with acute MI compared
with healthy controls. There was a
significant correlation between CEC
counts and C-reactive protein.
Data are mean or median (interquartile range).
ACS  acute coronary syndromes; CAD  coronary artery disease; CEC  circulating endothelial cell; CVD  cardiovascular disease; IB  immunobead; IL-6  interleukin-6; MACE  major adverse cardiovascular event;
MI  myocardial infarction; vWf  von Willebrand factor.
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Circulating Endothelial Cells October 17, 2006:1538–47George et al. (17) plotted the effects of coronary angio-
lasty on CEC counts in 10 patients listed for elective
oronary angioplasty. All patients had normal CEC counts
efore the procedure, with a peak increase in CEC counts to
to 15 cells/ml at 4 h after the procedure. The CEC counts
n peripheral venous and arterial blood taken at 4 h were
imilar. There was then a gradual decrease in CEC counts
ver the ensuing 20 h toward near-baseline CEC levels.
VD. Peripheral vascular disease is a well-established pre-
ictor of cardiovascular risk in which disease severity relates
o the level of vascular damage, prothrombotic markers, and
ndothelial dysfunction, all of which play a major role in
therosclerosis. There has been only 1 study to date designed
o examine CEC counts in PVD severity (Table 2). Makin et
l. (39) studied 4 patient groups, each of 20 patients, with
ower limb ischemic rest pain, intermittent claudication, and
cute MI, and healthy controls (the MI data has been
resented above). They showed that CEC counts were
levated in patients with ischemic rest pain compared with
ormal levels among the patients with intermittent claudi-
ation and in healthy controls. Furthermore, levels of CECs
orrelated with plasma tissue factor (associated with a
rothrombotic state) and vWf. Thus, increased CECs are
resent only in severe disease of the coronary (acute MI,
nstable angina) and peripheral circulation (ischemic rest
ain), not in relatively stable disease of those vessels (i.e.,
table angina and intermittent claudication).
troke, hypertension, and AF. Because stroke is well
nown to be associated with endothelial abnormalities, it
ould be reasonable to speculate that CECs would also be
ncreased in patients with this condition, and that they
ould correlate with other indices of endothelial dysfunc-
ion. There have been 2 studies investigating CEC quanti-
cation in stroke. Freestone et al. (67) looked at patients
ith AF and stroke as part of a broader study of CECs in
F. They found higher levels of CECs in patients with
oncurrent AF and a history of stroke compared with
ealthy controls in sinus rhythm, and that CECs correlated
ith vWf. Nadar et al. (68) studied 29 patients presenting
ith stroke and hypertension (but no AF), and compared
hem with 30 high-risk hypertensive patients (Table 2) and
0 normotensive controls. Compared with the other 2
roups, the patients with acute ischemic stroke had signif-
cantly higher numbers of CECs per milliliter in venous
lood and higher levels of vWf and soluble E-selectin. In
ddition, the numbers of CECs correlated with both vWf
nd soluble E-selectin.
It is somewhat surprising that CEC counts were normal
n high-risk hypertensive controls because these patients are
nown to have marked endothelial dysfunction (25,26,69).
owever, it would seem that perhaps, as in the case of
hronic stable angina, a certain threshold level of endothelial
njury is required to cause CEC detachment from the
ndothelium. Notably, Bull et al. (43) reported increased
ECs in primary and secondary pulmonary hypertension. Eeart failure. Chong et al. (37) tested the hypothesis of a
lear relationship between the endothelial dysfunction (de-
ned by FMD, vWf, and soluble thrombomodulin) and
ECs in patients with chronic HF. Among the patients
ith HF there was a 3-fold higher level of CECs, but no
ifference in soluble thrombomodulin, compared with con-
rols. In addition, there was also a positive correlation
etween CECs and vWF, confirming the ability of CECs to
redict endothelial dysfunction. They subsequently reported
qually raised CECs in acute HF as in chronic HF (70).
iabetes. McClung et al. (71) investigated the presence of
ECs in the peripheral blood of 25 patients with diabetes
ellitus and in 9 nondiabetic control donors (Table 2).
hey showed that patients with diabetes mellitus had an
levated number of CECs compared with healthy controls.
owever, CEC counts did not correlate with the levels of
emoglobin A1c and were independent of plasma glucose
evels.
ECs and the prediction of cardiovascular events. Koc
t al. (72) asked whether or not CEC counts would be
redictive of cardiovascular events in hemodialysis subjects
t increased risk for CVD. They studied 2 patient cohorts:
n the first, CEC numbers were determined in 29 hemodi-
lysis patients followed up for a mean of 470 days; in the
econd cohort of 44 hemodialysis patients, they analyzed the
ssociation between CEC counts with other markers of
ascular inflammation. Seven of the 19 subjects with ele-
ated CECs (defined as 19 cells/ml) had cardiovascular
vents during follow-up, compared with no events among
he low CEC count population (p  0.04). Among the
econd cohort, there was a positive correlation between
EC counts and high-sensitivity C-reactive protein,
nterleukin-6, interleukin-10, monocyte chemoattractant
rotein-1, and soluble vascular cell adhesion molecule-1.
Lee et al. (65) asked the same question in patients
dmitted to a coronary care unit with the diagnosis of an
cute coronary syndrome. Compared with interleukin-6 (a
roinflammatory cytokine) and plasma vWf, high numbers
f CECs 48 h after admission were the only predictor of
oth major adverse coronary events and death at 1 month
nd 1 year.
Although strictly speaking not CVD, when defining
ECs by intracellular vWf and the expression of the VEGF
eceptor KDR, Mutunga et al. (73) reported high numbers
f CECs in those patients who died of septic shock
ompared with those who had similar disease but survived.
S THERE A RELATIONSHIP
ETWEEN CECs AND EPCs?
current theory is that increased numbers of CECs reflect
evere endothelial damage, and that therefore there are areas
f the subendothelium that are denuded and that potentially
ay attract platelets (9). In parallel is the hypothesis that
PCs are restorative/regenerative cells, possibly destined to
Table 2. CEC Quantification in Other Cardiovascular Disease States
Author Year
Method
of CEC
Isolation Patient Type
Number of
Patients
Median/Mean  SD
CEC Counts in Active
Group in Cells/ml (Range) Adjusted Variables Main Findings
Peripheral artery disease
Makin et al. (39)
2004 IB Acute MI
Ischemic rest pain
IC
Healthy controls
26
20
20
20
7.6 (1.5–43.5)
3.5 (2.0–5.8)
1.1 (0.6–2.9)
1.0 (0.5–1.7)
Nil, but groups well
matched
Patients with ischemic rest pain have significantly
elevated CEC counts, but not as high as for
acute MI. CEC counts correlated with vWf
and tissue factor levels.
Stroke and high blood
pressure (HBP)
Nadar et al. (68)
2005 IB Stroke and HBP
HBP controls
Healthy controls
29
30
30
15.5 (10.8–20.7)
3.1 (1.6–4.8)
2.7 (1.6–3.7)
Age, gender, glucose,
creatinine, clinical
group, systolic
blood pressure,
vWf, E-selectin
Acute ischemic stroke is associated with increased
numbers of CECs compared with both healthy
and hypertensive controls (p  0.001). CECs
significantly correlated with soluble E-selectin
and vWf.
Atrial fibrillation (AF)
Freestone et al. (67)
2005 IB AF patients with:
Acute MI
Acute stroke
Acute LVF
Chronic stable AF
Healthy controls in SR
22
28
20
28
20
9 (6–15)
15 (11–33)
10 (6–19)
5 (3–10)
4.5 (1.6–7.2)
Smoking No increased CEC levels with chronic stable AF.
CEC counts are increased in AF when
associated with MI, stroke, or heart failure.
CEC counts correlated with vWf levels.
Heart failure
Chong et al. (37)
2004 IB Chronic LVF
Healthy controls
30
20
11.8 (4.6–18.4)
3.7 (1.3–7.2)
None for CEC
quantification, but
groups well
matched
CEC counts significantly higher in patients with
LVF versus healthy controls (p  0.001).
CEC counts were inversely correlated with
BNP and positively correlated with vWf.
Diabetes mellitus
McClung et al. (71)
2005 IB DM
Healthy controls
25
9
69  30 (35–126)
10  5 (3–18)
Gender, age, BMI,
HbAIC
CEC counts in DM are significantly higher than
healthy controls.
Pulmonary hypertension
(PHT)
Bull et al. (43)
2003 IB Primary PHT
Secondary PHT
Normal controls
5
11
12
33.1  1.9
27.2  6.9
3.5  1.3
Unclear CECs correlated strongly with SBP, DBP, and
mean arterial pressure, not with cardiac output
or pulmonary vascular resistance.
AF  atrial fibrillation; BMI  body mass index; BNP  brain naturetic peptide; DBP  diastolic blood pressure; DM  diabetes mellitus; HbAIC  haemolglobin AIC; IC  intermittent claudication; LVF  left ventricular failure;
SBP  systolic blood pressure; SR  sinus rhythm; vWf  von Willebrand factor; other abbreviations as in Table 1.
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Circulating Endothelial Cells October 17, 2006:1538–47eplace/renew damaged areas of the intima (15,74–77). Are
hese theories related?
re numbers of CECs and EPCs inversely related? The
urrent literature has largely shown elevated numbers of
ECs, yet reduced numbers of EPCs, among a broad
pectrum of patients with CVD and its risk factors, raising
he suggestion of an inverse relationship (37,39,63,71,76–
1). It may be that the disease process that drives mural
ndothelial cells into the blood to become CECs also
nfluences (reduces) levels of EPCs. However, the reality is
ikely to be far more complex than merely a reciprocal
ituation. For example, in acute MI elevated numbers of
oth CECs and EPCs have been shown (17,39,63–66,82–
4). Furthermore, stimulatory/therapeutic factors (e.g., st-
tins and endurance training) among patients with CAD
eads to both improved endothelial function and increased
PC counts, although the relationship between therapeutic
actors and decreasing CEC counts has not been studied for
VD (85–87). In addition, there have been no studies to
ate that have actually attempted to quantify both CECs
nd EPCs simultaneously in the same patient population.
re CECs and EPCs phylogenetically related? However,
uch of the above presupposes that CECs and EPCs are
ntirely different cells. This view may be premature, and the
cells types may share a common cell biology. Although
ltimately defined by different laboratory techniques (im-
unomagnetic beads or flow cytometry for CECs alongside
ow cytometry and/or tissue culture for EPCs), the initial
roblem is with the distribution of the particular molecules
urported to define each cell type (i.e., CD146 for CECs
nd any combination of CD34, CD133, VEGFR-2, and so
n, for EPCs) (12–17). It seems likely that under certain
onditions, a small number of cells bear both CD146 and
D34 (53,88–90), possibly leading to difficulties in inter-
retation, especially as both CECs and EPCs are present in
ery small numbers. Notably, for example, Nakatani et al.
91) estimated that 0% to 18% of CD146-defined CECs
rom patients with Kawasaki disease were also positive for
D133. Although much development work has been per-
ormed in vitro (92) (e.g., changes in proportions of cells
earing CD34 and CD133) (90), a parallel with the clinical
ituation cannot necessarily be assumed.igure 3. Simplified discrimination of endothelial progenitor cells from circula
ndothelial cell, EPC  endothelial progenitor cell.Some of these issues may be partially resolved with
dditional phenotyping. The endothelioid nature of CECs
nd EPCs is generally presumed by staining for vWf, lectins
e.g., Ulex europaeus), endothelial nitric oxide synthase, and
cetylated low-density lipoprotein cholesterol (9,90). How-
ver, the anatomical origin of CECs can be traced with the
se of CD36, a microvascular marker (40,43,47,58,63,65),
nd others have used E-selectin and intracellular adhesion
olecule-1 expression to quantify activation (40,43,53,63).
lthough it is known that atherosclerosis is an arterial
isease, it is not known whether or not CECs arise from the
rterial or the venous circulation, although the use of CD45
o exclude a leukocyte origin for these cells is common
53,58,65).
he heterogenous nature of EPCs. As mentioned, a
roblem is the definition of an EPC, because many markers
re available (CD34, CD133, VEGFR-2) (12–16,90). A
urther growing issue with EPCs is the question of a
onocytic origin for these cells. Current data tend to
uggest that under angiogenic stimulation, monocytes
bearing CD14) have the capacity to develop an endothelial
henotype with expression of specific surface markers and
ven form cord- and tubular-like structures in vitro (93,94).
he relationship between monocytes and EPCs is complex;
here are clearly EPCs that are nonmonocytic, but there also
eem to be monocytes that possess both functional charac-
eristics and, perhaps, surface markers (in lower numbers)
or CECs and EPCs, and vice versa (95–97). However,
espite differences in their derivation, EPCs possess the
ommonality of being capable of augmenting revasculariza-
ion and endothelial regeneration. This problem of hetero-
eneity is compounded by the different names (endothelial
utgrowth cells [98], circulating angiogenic cells [99],
ndothelial-like cells [100]) given to possibly overlapping
ell types.
onclusions. The measurement of immunologically de-
ned CECs and EPCs in venous blood now represents an
mportant and novel technique for assessment of endothelial
njury and repair (Fig. 3). Circulating endothelial cells are
iomarkers of damage, and high levels predict a poor
utcome (9,65). Endothelial progenitor cells are biomarkers
f repair with therapeutic potential, and low levels predict ation endothelial cells. CEC  circulating endothelial cell, EC  mural
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October 17, 2006:1538–47 Circulating Endothelial Cellsoor outcome (76,101). It may be that damage to mural
ndothelial cells that lead to increased CECs is physiolog-
cally restored by EPCs. Levels of CECs in the bloodstream
ave been shown to significantly correlate with several
ell-established plasma and physiological markers of endo-
helial function, are technically simple to measure (102), are
levated in a wide spectrum of conditions, and are predictive
f major adverse cardiovascular end points and death in
atients with acute coronary syndromes. As such, they
epresent one of the first specific cellular markers to provide
direct link with the pathophysiology of CVD. Bonello et
l. (103) have shown increased CECs and mobilization of
PCs after coronary angioplasy.
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